Stock 600671 HANGZHOU TIANMUSHAN PHARMACEUTICAL ENTERPRISE CO.,LTD
Add to a list
To use this feature you must be a member
Log inSign up

Financials Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd

Equities

600671

CNE000000BF3

Pharmaceuticals

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-04-28 pm EDT 		5-day change 1st Jan Change
8.79 CNY -1.12% Intraday chart for Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd +10.57% -24.61%
Apr. 26 Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 15 Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 1,948 1,500 1,049 1,094 1,158 1,420
Enterprise Value (EV) 1 2,004 1,573 1,154 1,185 1,232 1,437
P/E ratio -229 x 30 x -25.9 x -37.4 x -17.3 x -37.1 x
Yield - - - - - -
Capitalization / Revenue 5.44 x 5.05 x 5.07 x 7.44 x 10.6 x 11.7 x
EV / Revenue 5.59 x 5.3 x 5.59 x 8.06 x 11.3 x 11.8 x
EV / EBITDA 95.5 x -228 x -179 x -60.6 x -42.4 x -134 x
EV / FCF 43.2 x -8.13 x 195 x 28.1 x 32.5 x -180 x
FCF Yield 2.32% -12.3% 0.51% 3.55% 3.07% -0.56%
Price to Book 33.5 x 14.2 x 14.4 x 24.2 x -79.2 x 38.2 x
Nbr of stocks (in thousands) 121,779 121,779 121,779 121,779 121,779 121,779
Reference price 2 16.00 12.32 8.610 8.980 9.510 11.66
Announcement Date 4/27/19 6/12/20 5/12/21 4/29/22 4/25/23 4/15/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 358.5 297.1 206.6 147.1 108.9 121.8
EBITDA 1 20.99 -6.907 -6.454 -19.56 -29.02 -10.72
EBIT 1 7.669 -19.54 -15.12 -29.19 -43.89 -21.89
Operating Margin 2.14% -6.58% -7.32% -19.85% -40.3% -17.97%
Earnings before Tax (EBT) 1 0.4361 52.87 -50.61 -33.73 -72.37 -36.31
Net income 1 -8.882 50.11 -40.52 -29.8 -67.56 -38.28
Net margin -2.48% 16.87% -19.61% -20.26% -62.04% -31.43%
EPS 2 -0.0700 0.4100 -0.3327 -0.2400 -0.5500 -0.3143
Free Cash Flow 1 46.41 -193.6 5.93 42.11 37.87 -8
FCF margin 12.95% -65.17% 2.87% 28.64% 34.78% -6.57%
FCF Conversion (EBITDA) 221.07% - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 4/27/19 6/12/20 5/12/21 4/29/22 4/25/23 4/15/24
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 56 73 106 91.4 73.7 16.8
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 2.668 x -10.56 x -16.39 x -4.674 x -2.538 x -1.567 x
Free Cash Flow 1 46.4 -194 5.93 42.1 37.9 -8
ROE (net income / shareholders' equity) -6.01% 44.7% -45.5% -41.5% -212% -130%
ROA (Net income/ Total Assets) 1.07% -2.4% -1.95% -4.32% -7.81% -4.23%
Assets 1 -829.7 -2,087 2,079 690.2 865.2 904
Book Value Per Share 2 0.4800 0.8700 0.6000 0.3700 -0.1200 0.3000
Cash Flow per Share 2 0.7100 0.2100 0.0600 0.1800 0.3500 0.8000
Capex 1 37.5 94.7 11.8 4.71 3.52 8.96
Capex / Sales 10.45% 31.86% 5.73% 3.2% 3.23% 7.35%
Announcement Date 4/27/19 6/12/20 5/12/21 4/29/22 4/25/23 4/15/24
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
HANGZHOU TIANMUSHAN PHARMACEUTICAL ENTERPRISE CO.,LTD Stock Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd
-24.61% 149M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.70% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+26.74% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.52% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.94% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.21% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.43% 231B
NOVARTIS AG Stock Novartis AG
+4.71% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.53% 195B
AMGEN INC. Stock Amgen Inc.
-5.13% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 600671 Stock
  4. Financials Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd